The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients
Trial Parameters
Brief Summary
Academic research project monitoring the effect of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) on multiple sclerosis-associated lower urinary tract symptoms.
Eligibility Criteria
Inclusion Criteria: * Subjects (male and female) aged 18 and over * Subjects with signed informed consent * Subjects able to undergo examination according to the protocol * Patients indicated by neurologists to perform AHSCT or treated with the closest similar disease-modifying therapy (control group) Exclusion Criteria: * Subjects with a history of bladder cancer * Subjects after previous pelvic radiotherapy * Subjects with evidence of microscopic or macroscopic hematuria * Subjects with a history of bladder reconstruction (augmentation cystoplasty, catheterizable stoma), subjects after cystectomy * Treatment with botulinum toxin injection into the bladder wall in the last 12 months * Patients in whom the pharmacological treatment of the lower urinary tract has not been stable in the last 3 months and is being adjusted * Patients whose lower urinary tract symptoms are not stable for at least 3 months * Patients with a permanent catheter * Patients with recurrent symptomatic lower urin